Company intelligence / Profile preview

FerruMax Pharmaceuticals, Inc.

Boston / general Massachusetts area [2][1], Massachusetts, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

FerruMax Pharmaceuticals developed FMX-8, a recombinant fusion protein targeting hepcidin to treat anemia of chronic disease. The company advanced FMX-8 through early clinical trials including Phase I and II studies in both healthy volunteers and patients with anemia due to chronic kidney disease. However, all development was discontinued after termination of the Phase II trial; no recent reports or ongoing programs are available[4][1].

Therapeutic areas: Hematology
Modalities: Recombinant fusion proteinsSmall molecules (possible, but primary focus is on fusion proteins)
Industry: Biotech

Drug pipeline

1 asset

FMX-8

Beyond the preview

Go deeper on FerruMax Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FerruMax Pharmaceuticals, Inc..

Explore the full profile